| Literature DB >> 33492962 |
Yuhua Zhong1, Shaoxi Yang2, Jianyu Cui2, Jie Wang2, Lin Li2, Yilin Chen2, Junjie Chen2, Pengju Feng3, Shun Huang2, Hongsheng Li2, Yanjian Han2, Ganghua Tang2, Kongzhen Hu2.
Abstract
Glycogen synthase kinase-3β (GSK-3β), a cytoplasmic serine/threonine protein kinase, is involved in several human pathologies including Alzheimer's disease, bipolar disorder, diabetes, and cancer. Positron emission tomography (PET) imaging of GSK-3β could aid in investigating GSK-3β levels under normal and pathological conditions. In this study, we designed and synthesized fluorinated PET radioligands starting with recently identified isonicotinamide derivatives that showed potent affinity to GSK-3β. After extensive in vitro inhibitory activity assays and analyzing U87 cell uptake, we identified [18F]10a-d as potential tracers with good specificity and high affinity. They were then subjected to further in vivo evaluation in rodent brain comprising PET imaging and metabolism studies. The radioligands [18F]10b-d penetrated the blood-brain barrier and accumulated in GSK-3β-rich regions, including amygdala, cerebellum, and hippocampus. Also, it could be specifically blocked using the corresponding standard compounds. With these results, this work sets the basis for further development of novel 18F-labeled GSK-3β PET probes.Entities:
Keywords: 18F-labeled; GSK-3β; PET; brain; isonicotinamide
Year: 2021 PMID: 33492962 DOI: 10.1021/acs.molpharmaceut.0c01133
Source DB: PubMed Journal: Mol Pharm ISSN: 1543-8384 Impact factor: 4.939